1. Home
  2. AGCC vs CCCC Comparison

AGCC vs CCCC Comparison

Compare AGCC & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AGCC

Agencia Comercial Spirits Ltd Class A Ordinary Shares

HOLD

Current Price

$14.80

Market Cap

438.9M

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$3.94

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGCC
CCCC
Founded
2020
2015
Country
Taiwan
United States
Employees
23
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
438.9M
404.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AGCC
CCCC
Price
$14.80
$3.94
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$12.20
AVG Volume (30 Days)
33.5K
4.0M
Earning Date
05-23-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.45
EPS
N/A
N/A
Revenue
N/A
$35,947,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$168.97
N/A
Revenue Growth
N/A
1.02
52 Week Low
$4.23
$1.69
52 Week High
$25.73
$5.17

Technical Indicators

Market Signals
Indicator
AGCC
CCCC
Relative Strength Index (RSI) 45.82 47.16
Support Level $13.42 $2.10
Resistance Level $16.61 $4.60
Average True Range (ATR) 0.88 0.40
MACD 0.13 -0.06
Stochastic Oscillator 13.20 16.26

Price Performance

Historical Comparison
AGCC
CCCC

About AGCC Agencia Comercial Spirits Ltd Class A Ordinary Shares

Agencia Comercial Spirits Ltd specializes in the procurement, distribution, and sale of high-quality whiskies, including both bottled and cask whisky in both Taiwan and international markets. The company's product portfolio includes the distribution of bottled whisky, raw cask whisky, and proprietary brand whisky.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: